Symbiotec Pharmalab IPO Day 1: Subscription status, review — here's what you need to know
- Symbiotec Pharmalab IPO opened on August 24, 2026, closing Day 1 with 0.79x overall subscription.
- NII (bHNI) was the standout category, jumping 437.9% to 1.56x.
- Retail subscription surged 370.0% to 0.94x.
- QIBs remained largely inactive at 0.35x.
- The company reported FY 2026 revenue of ₹869.15 crores and profit of ₹109.90 crores.
*this image is generated using AI for illustrative purposes only.
Symbiotec Pharmalab’s IPO closed with a colossal late-stage surge, ending at 71.19x overall subscription. Qualified Institutional Buyers (QIB) drove the momentum, jumping sharply in the final hours to reach 172.03x. The Non-Institutional Individual (NII) category remained robust, while Retail interest also ticked up significantly by close.
Final Subscription Status
The issue ended its final day with significant momentum from institutional investors who accelerated bids sharply after 2 PM. The Non-Institutional Individual (NII) category remained strong, with bHNI leading individual demand.
| Category | Subscription Multiple |
|---|---|
| QIB | 172.03x |
| NII (bHNI) | 82.92x |
| NII (sHNI) | 54.98x |
| Retail | 12.84x |
| Employees | 15.29x |
| Overall | 71.19x |
Subscription Progression
Demand accelerated sharply throughout the four-day window. While early days saw modest interest, Day 4 brought a decisive institutional push that lifted the total multiple significantly from 37.95x to 71.19x in the final session.
| Day | Date | QIB | NII (bHNI) | NII (sHNI) | Retail | Total |
|---|---|---|---|---|---|---|
| Day 1 | 24-08-2026 | 0.35x | 1.56x | 0.77x | 0.94x | 0.79x |
| Day 2 | 25-08-2026 | 0.54x | 4.03x | 2.42x | 2.08x | 1.83x |
| Day 3 | 26-08-2026 | 0.59x | 13.77x | 11.11x | 5.00x | 5.24x |
| Day 4 | 27-08-2026 | 172.03x | 82.92x | 54.98x | 12.84x | 71.19x |
Intra-day Timeline (27-08-2026)
The standout move occurred between 11:15 AM and 4:15 PM, where QIB subscription raced ahead, more than tripling again in the final hours to reach 172.03x. Total subscription jumped +676.3% today (from 9.17x to 71.19x).
| Time (IST) | QIB | NII (bHNI) | Retail | Total |
|---|---|---|---|---|
| 11:15 | 0.63x | 23.10x | 6.76x | 9.17x |
| 12:15 | 2.01x | 28.88x | 8.07x | 12.07x |
| 13:15 | 10.40x | 35.50x | 9.18x | 17.19x |
| 14:15 | 17.62x | 32.34x | 6.47x | 18.36x |
| 15:15 | 63.13x | 49.55x | 11.38x | 37.95x |
| 16:15 | 172.03x | 54.52x | 12.40x | 70.94x |
| 17:15 | 172.03x | 54.98x | 12.84x | 71.19x |
About the Company
Symbiotec Pharmalab Limited is a research and development-driven pharmaceutical and biotechnology company. It holds a global leadership position in corticosteroid and steroidal-hormone APIs, with a 38.2% global volume market share in corticosteroids. Founded in 2002, the company operates as a CDMO for specialty pharmaceutical companies globally.
Financial Highlights
The company reported consistent revenue growth over the last three fiscal years. Total equity increased significantly, reflecting retained earnings and capital efficiency.
| Particulars | FY 2026 (₹ crores) | FY 2025 (₹ crores) | FY 2024 (₹ crores) |
|---|---|---|---|
| Revenue from Operations | 869.15 | 751.55 | 716.25 |
| Total Profit (PAT) | 109.90 | 96.79 | 100.06 |
| Total Equity | 1149.59 | 814.71 | 714.84 |
Objects of the Issue
- Prepayment and/or repayment of outstanding borrowings: ₹112.50 crores
- General corporate purposes: Balance net proceeds
Risk Factors
- High Revenue Concentration in APIs: 96.07% of revenue derived from API sales in Fiscal 2026.
- Regulatory Compliance Risks: Manufacturing facilities subject to inspections; recent US FDA Form 483 observations noted.
- Significant Export Revenue Exposure: 67.04% of revenue from external customers outside India in Fiscal 2026.
What's Next
- Allotment Date: 2026-08-28
- Listing Date: 2026-09-01
- Basis of Allotment: Pro-rata basis expected given high subscription multiples in NII and Retail categories.
Will the lack of QIB interest (0.35x) signal potential listing price volatility or indicate institutional skepticism regarding Symbiotec's API concentration risks?
How might the recent US FDA Form 483 observations impact long-term investor confidence and export stability given that 67% of revenue comes from external customers?
Could the significant late-day retail and NII momentum lead to oversubscription by the final close on August 27, or will the issue remain undersubscribed?
16
Access 50+ Readymade Screeners 
Use 200+ Custom Filters 
Get Full Market Insights 
